Xue-Bin Ran, Ling-Wen Ding, Qiao-Yang Sun, Henry Yang, Jonathan W Said, Lao Zhentang, Vikas Madan, Pushkar Dakle, Jin-Fen Xiao, Xinyi Loh, Ying Li, Liang Xu, Xiao-Qiang Xiang, Ling-Zhi Wang, Boon Cher Goh, De-Chen Lin, Wee Joo Chng, Soo-Yong Tan, Sudhakar Jha, H Phillip Koeffler
UNLABELLED: Despite the remarkable clinical responses achieved with immune checkpoint blockade therapy, the response rate is relatively low and only a subset of patients can benefit from the treatment. Aberrant RNA accumulation can mediate IFN signaling and stimulate an immune response, suggesting that targeting RNA decay machinery might sensitize tumor cells to immunotherapy. With this in mind, we identified an RNA exoribonuclease, XRN1, as a potential therapeutic target to suppress RNA decay and stimulate antitumor immunity...
March 15, 2023: Cancer Research